Marker Therapeutics (NASDAQ:MRKR – Get Free Report) and PTC Therapeutics (NASDAQ:PTCT – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.
Earnings & Valuation
This table compares Marker Therapeutics and PTC Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Marker Therapeutics | $3.55 million | 4.09 | -$12.16 million | ($0.41) | -2.12 |
| PTC Therapeutics | $1.73 billion | 3.06 | $682.64 million | ($1.40) | -45.35 |
PTC Therapeutics has higher revenue and earnings than Marker Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Marker Therapeutics and PTC Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Marker Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
| PTC Therapeutics | 1 | 3 | 10 | 1 | 2.73 |
Marker Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 1,049.43%. PTC Therapeutics has a consensus price target of $99.23, suggesting a potential upside of 56.29%. Given Marker Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Marker Therapeutics is more favorable than PTC Therapeutics.
Profitability
This table compares Marker Therapeutics and PTC Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Marker Therapeutics | N/A | -56.96% | -47.82% |
| PTC Therapeutics | -9.17% | N/A | -0.10% |
Risk & Volatility
Marker Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.
Insider & Institutional Ownership
22.4% of Marker Therapeutics shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Marker Therapeutics beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.
About Marker Therapeutics
Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.
About PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
